Close Menu

NEW YORK (360Dx) – Based on an unexpected finding from a study of inflammation, researchers at VIB and Ghent University in Belgium have developed an immunoassay that may improve the diagnosis of familial Mediterranean fever (FMF) and lead to earlier therapy.

The scientists, led by Mohamed Lamkanfi at the Center for Inflammation Research at VIB and Ghent University, are currently validating the assay and are transferring it to other clinical laboratories. In addition, they are in discussion with a potential licensing partner who might commercialize the test as a diagnostic kit.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.